morcellation Flashcards

RANZCOG guideline

1
Q

What are the risks of morcellation (3)

A
  • Injury to surround structures
  • Dissemination - if malignant upstaging the disease and affecting the need for adjutant treatment
  • Assessment of pathology - the loss of anatomical relationships may complicate analysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How to safely use Electromechanical morcellation

A
  • Should be resitricted to the use of AGES RANZCOG level 5 and above
  • non suspicion of malignancy pre op or periop
  • Maintain the tip of the instrument in view at all times
  • Caintain control of the specimen at all times
  • Feed the specimen into the morcellatory in a controlled manner
  • Minimalse spillage fragments when ever possible
  • post morcellation retrieve all marcoscopic fragments
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How to manage risk of dissemination

A

o need to adequate case selection
o ensure pre op assessment including pap smear, USS, tumor markers if indicated, endometrial sampling, extended imaging
o Patient consent - they must be engaged in the discussion
o Intraoperative assessment is generally poor but if it appears suspicious call for a gynae onc opinion intraop, abandon, use a technique that avoids dissemination eg endopouch or minilaparotomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the incidence of leiomyosarcomas

A

The incidence of leiomyosarcoma (LMS) has been variably quoted at between 0.02 to 0.3%, depending on the study population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Reported demographic risk factors for LMS include: (7)

A
  • Age (mean age of diagnosis: 60)
  • Menopausal status
  • African American ethnic background
  • Current or prior tamoxifen exposure
  • History of pelvic Irradiation
  • Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) syndrome
  • Survivors of childhood retinoblastoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the clinical assessment should make you concerned about LMS?

A
  • Rapidly expanding mass
  • Postmenopausal bleeding or variants of abnormal uterine bleeding, in premenopausal women with an unusual pattern
  • Ascites
  • Lymphadenopathy
  • Evidence of secondary spread
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the imaging risk factors for LMS?

6

A
  • Large size or large interval growth
  • Tissue signal heterogeneity
  • Central necrosis
  • Ill-defined margins
  • Ascites
  • Metastases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

There are no tumor markers associated with LMS - what one indicator may be elevated ?

A

LDH indicating cell turn over

How well did you know this?
1
Not at all
2
3
4
5
Perfectly